23 Lung Cancer Clinical Trials in Atlanta, GA (2026)

Q: How do I join a clinical trial in Atlanta?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you.

Recruiting Lung Cancer Studies in Atlanta

NCT05236114Recruiting

GEMINI-NSCLC: NSCLC Biomarker Study

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition t...

Atlanta, GA1,200 participantsTempus AI

View Study Details

NCT05384626Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activ...

Atlanta, GAPHASE1840 participantsNuvalent Inc.

View Study Details

NCT05379985Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....

Atlanta, GAPHASE1754 participantsRevolution Medicines, Inc.

View Study Details

NCT07472517Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carbopla...

Atlanta, GAPHASE3670 participantsBoehringer Ingelheim

View Study Details

NCT06712355Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherap...

Atlanta, GAPHASE3621 participantsBioNTech SE

View Study Details

NCT06745908Recruiting

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enro...

Atlanta, GAPHASE3507 participantsImmunityBio, Inc.

View Study Details

NCT07100080Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy...

Atlanta, GAPHASE2500 participantsBristol-Myers Squibb

View Study Details

NCT06765109Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with...

Atlanta, GAPHASE3450 participantsNuvalent Inc.

View Study Details

NCT06452277Recruiting

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutat...

Atlanta, GAPHASE3444 participantsBayer

View Study Details

NCT07195695Recruiting

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions ...

Atlanta, GAPHASE3400 participantsBoehringer Ingelheim

View Study Details

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Atlanta, GAPHASE1400 participantsBayer

View Study Details

NCT07037758Recruiting

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to...

Atlanta, GAPHASE1380 participantsAmgen

View Study Details

NCT04429087Recruiting

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for w...

Atlanta, GAPHASE1300 participantsBoehringer Ingelheim

View Study Details

NCT07098338Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several ...

Atlanta, GAPHASE2278 participantsAstraZeneca

View Study Details

NCT06773910Recruiting

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of...

Atlanta, GAPHASE2250 participantsSCRI Development Innovations, LLC

View Study Details

NCT06667908Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can i...

Atlanta, GAPHASE2130 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT07080242Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroen...

Atlanta, GAPHASE1120 participantsSystImmune Inc.

View Study Details

NCT06495125Recruiting

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) ...

Atlanta, GAPHASE250 participantsEmory University

View Study Details

NCT03191149Recruiting

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period o...

Atlanta, GAPHASE246 participantsNational Cancer Institute (NCI)

View Study Details

NCT07140016Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some ...

Atlanta, GAPHASE140 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT05271292Recruiting

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (...

Atlanta, GAPHASE136 participantsChipscreen Biosciences, Ltd.

View Study Details

NCT04342429Recruiting

Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer

To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)...

Atlanta, GANA30 participantsEmory University

View Study Details

NCT06731270Recruiting

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

This phase II trial tests how well diclofenac works in treating patients non-small cell lung cancer (NSCLC) that may have spread from where it first started (primary site) to other places in the body ...

Atlanta, GAPHASE220 participantsEmory University

View Study Details

About Lung Cancer Clinical Trials in Atlanta

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 23 lung cancer clinical trials recruiting participants in Atlanta, GA. These studies are seeking a combined 8,466 participants. Research is being sponsored by Tempus AI, Nuvalent Inc., Revolution Medicines, Inc. and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Atlanta — FAQ

Are there lung cancer clinical trials in Atlanta?

Yes, there are 23 lung cancer clinical trials currently recruiting in Atlanta, GA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Atlanta?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.

Are clinical trials in Atlanta free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 23 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 16, 2026 from ClinicalTrials.gov